Applied BioCode (6598) - Total Liabilities

Latest as of September 2025: NT$343.23 Million TWD ≈ $10.81 Million USD

Based on the latest financial reports, Applied BioCode (6598) has total liabilities worth NT$343.23 Million TWD (≈ $10.81 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 6598 cash flow metrics to assess how effectively this company generates cash.

Applied BioCode - Total Liabilities Trend (2012–2024)

This chart illustrates how Applied BioCode's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Applied BioCode's assets to evaluate the company's liquid asset resilience ratio.

Applied BioCode Competitors by Total Liabilities

The table below lists competitors of Applied BioCode ranked by their total liabilities.

Company	Country	Total Liabilities
Estrella Immunopharma Inc. NASDAQ:ESLA	USA	$13.54 Million
Deniz Gayrimenkul Yatirim Ortakligi AS IS:DZGYO	Turkey	TL1.27 Billion
MCT Bhd KLSE:5182	Malaysia	RM550.59 Million
Ferrum S.A. BA:FERR	Argentina	AR$69.89 Billion
Tai Roun Products Co Ltd TW:1220	Taiwan	NT$968.75 Million
Lee Feed Mill Public Company Limited BK:LEE	Thailand	฿345.86 Million
DIGITAL CHOSUN Inc KQ:033130	Korea	₩15.05 Billion
Exagen Inc NASDAQ:XGN	USA	$44.69 Million

Liability Composition Analysis (2012–2024)

This chart breaks down Applied BioCode's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Applied BioCode (6598) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	7.96	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.50	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.33	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Applied BioCode's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Applied BioCode (2012–2024)

The table below shows the annual total liabilities of Applied BioCode from 2012 to 2024.

Year	Total Liabilities	Change
2024-12-31	NT$336.07 Million ≈ $10.59 Million	+1.16%
2023-12-31	NT$332.22 Million ≈ $10.47 Million	-16.19%
2022-12-31	NT$396.38 Million ≈ $12.49 Million	+241.68%
2021-12-31	NT$116.01 Million ≈ $3.65 Million	-17.27%
2020-12-31	NT$140.23 Million ≈ $4.42 Million	-25.55%
2019-12-31	NT$188.36 Million ≈ $5.93 Million	+131.55%
2018-12-31	NT$81.35 Million ≈ $2.56 Million	+34.89%
2017-12-31	NT$60.30 Million ≈ $1.90 Million	+17.84%
2016-12-31	NT$51.17 Million ≈ $1.61 Million	+25.81%
2015-12-31	NT$40.67 Million ≈ $1.28 Million	+4.37%
2014-12-31	NT$38.97 Million ≈ $1.23 Million	+64.93%
2013-12-31	NT$23.63 Million ≈ $744.47K	+18.18%
2012-12-31	NT$20.00 Million ≈ $629.95K	--

About Applied BioCode

TW:6598 Taiwan Medical Devices

Market Cap

$69.47 Million

NT$2.21 Billion TWD

Market Cap Rank

#20595 Global

#1233 in Taiwan

Share Price

NT$21.45

Change (1 day)

-2.28%

52-Week Range

NT$19.10 - NT$25.65

All Time High

NT$177.50